生物医药创新药动态更新：芦康沙妥珠单抗：在NSCLC、乳腺癌多种适应症及后线UC临床生存获益明显

Investment Rating - The report maintains an investment rating of "Leading the Market-B" for the biopharmaceutical industry, indicating an expected price increase exceeding the benchmark index by over 10% [9]. Core Insights - The biopharmaceutical industry has shown significant clinical breakthroughs, particularly with innovative drugs like sac-TMT, which demonstrates promising efficacy in treating various cancers, including NSCLC and TNBC [3][5]. - The report highlights the strong performance of sac-TMT in clinical trials, with an overall objective response rate (ORR) of 70.7% in first-line TNBC and 59.3% in non-squamous NSCLC [4][5]. - The report emphasizes the potential of sac-TMT in combination therapies, showing improved progression-free survival (PFS) rates compared to traditional treatments [4][5]. Summary by Sections Industry Performance - The biopharmaceutical sector has outperformed the market over the past year, with innovative drugs leading the way in clinical advancements [1]. Key Drug Analysis - sac-TMT, a novel TROP2 ADC, has shown significant clinical benefits across multiple cancer types, with a favorable safety profile and manageable adverse events [3][5]. - In clinical trials, sac-TMT demonstrated an ORR of 45% in previously treated EGFR-mutant NSCLC, significantly outperforming traditional therapies [4]. Clinical Trial Results - In first-line TNBC, sac-TMT achieved an ORR of 70.7% and a median PFS of 13.4 months, indicating strong anti-tumor activity [5]. - The report notes that sac-TMT's efficacy extends to various PD-L1 expression levels, with mPFS rates varying from 12.4 to 17.8 months depending on PD-L1 TPS [4].